{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T15:30:59Z","timestamp":1794497459413,"version":"4.9.1"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.intimp.2022.109269","type":"journal-article","created":{"date-parts":[[2022,9,29]],"date-time":"2022-09-29T02:06:40Z","timestamp":1664417200000},"page":"109269","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["The incidence, clinical characteristics and serological characteristics of anti-tumor necrosis factor-induced lupus in patients with inflammatory bowel disease: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"112","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1317-183X","authenticated-orcid":false,"given":"Cong","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-nuo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-ning","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Hong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.intimp.2022.109269_b0005","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/gut.2010.224154","article-title":"Guidelines for the management of inflammatory bowel disease in adults","volume":"60","author":"Mowat","year":"2011","journal-title":"Gut"},{"issue":"9317","key":"10.1016\/j.intimp.2022.109269_b0010","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.intimp.2022.109269_b0015","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial","volume":"56","author":"Sandborn","year":"2007","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.intimp.2022.109269_b0020","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa062897","article-title":"Maintenance therapy with certolizumab pegol for Crohn's disease","volume":"357","author":"Schreiber","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.intimp.2022.109269_b0025","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/ajg.2010.392","article-title":"The London position statement of the world congress of gastroenterology on biological therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?","volume":"106","author":"D'Haens","year":"2011","journal-title":"Am. J. Gastroenterol."},{"issue":"5","key":"10.1016\/j.intimp.2022.109269_b0030","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1080\/09546630410017275","article-title":"A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab","volume":"15","author":"Scheinfeld","year":"2004","journal-title":"J. Dermatolog. Treat."},{"issue":"1","key":"10.1016\/j.intimp.2022.109269_b0035","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.gastro.2006.11.041","article-title":"Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial","volume":"132","author":"Colombel","year":"2007","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.intimp.2022.109269_b0040","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1592\/phco.30.4.339","article-title":"Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis","volume":"30","author":"Wiens","year":"2010","journal-title":"Pharmacotherapy"},{"issue":"11","key":"10.1016\/j.intimp.2022.109269_b0045","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1002\/1529-0131(200011)43:11<2383::AID-ANR2>3.0.CO;2-D","article-title":"Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials","volume":"43","author":"Charles","year":"2000","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.intimp.2022.109269_b0050","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s13075-019-2028-2","article-title":"Anti-TNF-alpha-induced lupus","volume":"21","author":"De Bandt","year":"2019","journal-title":"Arthritis Res. Ther."},{"issue":"1","key":"10.1016\/j.intimp.2022.109269_b0055","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ibd.21362","article-title":"Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF-alpha antibody-treated patients with inflammatory bowel disease","volume":"17","author":"Beigel","year":"2011","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.intimp.2022.109269_b0060","doi-asserted-by":"crossref","unstructured":"S.J. Choi, S.M. Ahn, J.S. Oh, et al., Anti-tumor necrosis factor-induced lupus in patients with inflammatory bowel disease: a hospital-based cohort study from Korea, Therap. Adv. Gastroenterol. 14 (2021) 1756284821997794.","DOI":"10.1177\/1756284821997794"},{"issue":"9","key":"10.1016\/j.intimp.2022.109269_b0065","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1002\/ibd.20956","article-title":"Adalimumab safety in global clinical trials of patients with Crohn's disease","volume":"15","author":"Colombel","year":"2009","journal-title":"Inflamm. Bowel Dis."},{"issue":"40","key":"10.1016\/j.intimp.2022.109269_b0070","doi-asserted-by":"crossref","first-page":"7265","DOI":"10.3748\/wjg.v23.i40.7265","article-title":"Genetic associations with adverse events from anti-tumor necrosis factor therapy in inflammatory bowel disease patients","volume":"23","author":"Lew","year":"2017","journal-title":"World J. Gastroenterol."},{"issue":"9","key":"10.1016\/j.intimp.2022.109269_b0075","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1080\/00365521.2019.1663260","article-title":"Lupus-like reactions in patients with inflammatory bowel disease treated with anti-TNFs are insidious adverse events: data from a large single-center cohort","volume":"54","author":"Macaluso","year":"2019","journal-title":"Scand. J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.intimp.2022.109269_b0080","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s40272-017-0267-8","article-title":"Serious adverse events associated with anti-tumor necrosis factor alpha agents in pediatric-onset inflammatory bowel disease and juvenile idiopathic arthritis in a real-life setting","volume":"20","author":"Pastore","year":"2018","journal-title":"Paediatr Drugs."},{"issue":"3","key":"10.1016\/j.intimp.2022.109269_b0085","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/jgh3.12291","article-title":"Anti-TNF-induced lupus in patients with inflammatory bowel disease","volume":"4","author":"Picardo","year":"2020","journal-title":"JGH Open."},{"issue":"8","key":"10.1016\/j.intimp.2022.109269_b0090","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1097\/MEG.0000000000000643","article-title":"Paradoxical articular manifestations in patients with inflammatory bowel diseases treated with infliximab","volume":"28","author":"Thiebault","year":"2016","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.intimp.2022.109269_b0095","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s10067-015-3140-6","article-title":"Infliximab-induced autoantibodies: a multicenter study","volume":"35","author":"Vaz","year":"2016","journal-title":"Clin. Rheumatol."},{"issue":"13","key":"10.1016\/j.intimp.2022.109269_b0100","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1097\/01.MIB.0000435435.91988.b6","article-title":"The incidence and predictors of lupus-like reaction in patients with IBD treated with anti-TNF therapies","volume":"19","author":"Yanai","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"issue":"4","key":"10.1016\/j.intimp.2022.109269_b0105","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/00054725-200407000-00002","article-title":"A pilot study of adalimumab in infliximab-allergic patients","volume":"10","author":"Youdim","year":"2004","journal-title":"Inflamm. Bowel Dis."},{"issue":"3","key":"10.1016\/j.intimp.2022.109269_b0110","doi-asserted-by":"crossref","DOI":"10.1186\/ar1715","article-title":"Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey","volume":"7","author":"De Bandt","year":"2005","journal-title":"Arthritis Res. Ther."},{"issue":"7","key":"10.1016\/j.intimp.2022.109269_b0115","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1136\/ard.2005.043166","article-title":"Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis","volume":"65","author":"Schiff","year":"2006","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2022.109269_b0120","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0016-5085(03)00701-7","article-title":"Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study","volume":"125","author":"Vermeire","year":"2003","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.intimp.2022.109269_b0125","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/j.gastro.2003.10.047","article-title":"The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients","volume":"126","author":"Colombel","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.intimp.2022.109269_b0130","doi-asserted-by":"crossref","unstructured":"F. Fatoye, T. Gebrye, C. Mbada, Global and regional prevalence and incidence of systemic lupus erythematosus in low-and-middle income countries: a systematic review and meta-analysis, Rheumatol. Int. (2022) (online).","DOI":"10.1007\/s00296-022-05183-4"},{"issue":"7","key":"10.1016\/j.intimp.2022.109269_b0135","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1093\/rheumatology\/kep080","article-title":"Anti-TNF-induced lupus","volume":"48","author":"Williams","year":"2009","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.intimp.2022.109269_b0140","doi-asserted-by":"crossref","first-page":"6821","DOI":"10.4049\/jimmunol.167.12.6821","article-title":"In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL","volume":"167","author":"Via","year":"2001","journal-title":"J. Immunol."},{"issue":"41","key":"10.1016\/j.intimp.2022.109269_b0145","doi-asserted-by":"crossref","first-page":"5848","DOI":"10.3748\/wjg.v18.i41.5848","article-title":"Changes of the cytokine profile in inflammatory bowel diseases","volume":"18","author":"Muzes","year":"2012","journal-title":"World J. Gastroenterol."},{"issue":"8","key":"10.1016\/j.intimp.2022.109269_b0150","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1097\/MIB.0000000000000392","article-title":"Extraintestinal manifestations of inflammatory bowel disease","volume":"21","author":"Vavricka","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"issue":"1","key":"10.1016\/j.intimp.2022.109269_b0155","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.autrev.2010.07.005","article-title":"Drug-induced lupus: an update","volume":"10","author":"Katz","year":"2010","journal-title":"Autoimmun. Rev."},{"issue":"8","key":"10.1016\/j.intimp.2022.109269_b0160","first-page":"1721","article-title":"Acetylation status is associated with serological changes but not clinically significant disease in patients receiving procainamide","volume":"26","author":"Mongey","year":"1999","journal-title":"J. Rheumatol."},{"issue":"3","key":"10.1016\/j.intimp.2022.109269_b0165","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4292\/wjgpt.v8.i3.155","article-title":"Strategies for overcoming anti-tumor necrosis factor drug antibodies in inflammatory bowel disease: Case series and review of literature","volume":"8","author":"Kothari","year":"2017","journal-title":"World J. Gastrointest Pharmacol. Ther."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922007536?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576922007536?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:45:13Z","timestamp":1761587113000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576922007536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":33,"alternative-id":["S1567576922007536"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109269","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The incidence, clinical characteristics and serological characteristics of anti-tumor necrosis factor-induced lupus in patients with inflammatory bowel disease: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2022.109269","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109269"}}